Email updates

Keep up to date with the latest news and content from Diagnostic Pathology and BioMed Central.

Open Access Commentary

Worldwide variations in EGFR somatic mutations: a challenge for personalized medicine

Pierre-Jean Lamy1* and William Jacot2

Author Affiliations

1 Laboratoire de Biologie Spécialisée et Oncogénétique, CRLC Val d'Aurelle-Paul Lamarque, 208, rue des Apothicaires, F-34298 France

2 Département d'Oncologie Médicale, CRLC Val d'Aurelle-Paul Lamarque, 208, rue des Apothicaires, F-34298 France

For all author emails, please log on.

Diagnostic Pathology 2012, 7:13  doi:10.1186/1746-1596-7-13

Published: 1 February 2012

Abstract

Two studies recently reported around 10% of EGFR activating mutations in triple negative breast cancers from Asian patients. However, we did not find any EGFR activating mutation in a series of 229 breast tumor samples from European patients. Like in lung cancer, the EGFR mutation profiles seem to be related to the ethnical origin of patients. This is an important point that should be considered when developing anti-EGFR therapies.

Keywords:
Breast Cancer; EGFR; activating mutations; triple negative; geographic variations